Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen

Key facts

Study ID
NCT04972227
Run by
Tisento Therapeutics
People needed
48
Starts
2021-09-10
Expected to finish
2022-04-18
Last updated by the study team
2024-08-13

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.